Navigation Links
Janssen Pharmaceuticals, Inc. Launches Online Tools on

RARITAN, N.J., Aug. 16, 2011 /PRNewswire/ -- To assist healthcare professionals in managing their patients' pain, Janssen Pharmaceuticals, Inc. (JPI) today launched several new resources and tools on, an online program designed to support appropriate and responsible treatment of pain. Introduced in early 2010, and its many educational materials have been viewed by thousands of physicians and pharmacists, both via its website and at medical conferences.



"Millions of adult Americans suffer with acute or chronic pain. Determining how to treat pain poses a challenge to both physicians and patients," said Steven Passik, PhD, Professor of Psychiatry and Anesthesiology at Vanderbilt University Medical Center.* "It is important to ensure that issues often associated with opioid pain medicines, including abuse, addiction, misuse and diversion, do not prevent patients who need relief from having access to appropriate pain treatment. The tools and content offered on may help physicians better understand how to strike the challenging balance between safeguarding patients and ensuring they have the care they need."

Clinical materials newly added to the website include a variety of pain and risk assessments intended to help physicians evaluate pain, manage adverse events, identify aberrant drug-related behaviors, monitor long-term therapy, facilitate patient education and communication, and document treatment progress when using opioid therapies. Also featured is general education content authored by experts related to safe and responsible opioid prescribing and pain management.

"Pain medications play an important role in the treatment of pain when used correctly," said Paul Chang, M.D., Vice President of Medical Affairs at Janssen Pharmaceuticals, Inc. "We want to make sure we equip physicians with the appropriate resources and tools to help them safely and effectively use opioids in their practice so that patients are neither undertreated nor unnecessarily exposed to risk." was developed in consultation with expert leaders in pain management, psychology, and addiction medicine. The written content covers a range of topics related to the appropriate prescribing of opioid analgesics and offers case studies to help healthcare professionals. The website is designed both to help physicians ensure that patients suffering from chronic pain have access to necessary treatment, and to address knowledge gaps around pain medication prescribing practices, to reduce the chances of misuse and abuse.

About pain
Pain is the most common reason people seek medical attention.  Failure to treat acute pain promptly and appropriately at the time of injury, during initial medical and surgical care, and at the time of transition to community-based care, can contribute to the development of chronic pain syndromes.  An estimated 42.6 million Americans age 20 and over suffer from chronic pain, according to information from the Centers for Disease Control and Prevention (CDC) and the American Pain Foundation (APF). Chronic pain is the most common cause of long-term disability. Despite the number of people who experience pain, it is often undertreated.

About is a free online resource sponsored by Janssen Pharmaceuticals, Inc.  It features content addressing the concerns of healthcare professionals about the appropriate and responsible prescribing of opioid pain therapies.  It is not meant to substitute for the independent medical judgment of a physician or other healthcare professional relative to diagnostic and treatment options of a specific patient's medical condition.

About Janssen Pharmaceuticals, Inc.
As a member of the Janssen Pharmaceutical Companies, Janssen Pharmaceuticals, Inc. is dedicated to addressing and solving some of the most important unmet medical needs of our time.  Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to individuals with serious conditions, and to physicians throughout the world.

For more information about Janssen Pharmaceuticals, Inc. or its products visit us at, or follow us on Twitter at

*Dr. Passik is a consultant to Janssen Pharmaceuticals, Inc. and received compensation for his prior contributions to   

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
4. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
8. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
10. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
11. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):